BOSTON, April 23, 2024 /PRNewswire/ — Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan.
Participants of this round are:
Beyond Next Ventures Inc.
The University of Tokyo Edge Capital Partners Co., Ltd.
Keio Innovation Initiative, Inc.
OSAKA University Venture Capital Co., Ltd.
This boosts the accumulative funding raised by Red Arrow Therapeutics to nearly $5.5M, along with previous funding from The University of Tokyo Edge Capital Partners Co., Ltd., University of California, Berkeley’s accelerator SkyDeck , and other non-dilutive funding.
Emerging from the University of Tokyo’s Cabral Lab in 2021, Red Arrow Therapeutics Inc. develops pH-sensing nanomedicine drug delivery technologies for multiple therapeutic areas such as oncology. Headquartered in Boston, Massachusetts, the company is committed to delivering cutting-edge technology for patients in need worldwide.
The Seed extension round will allow Red Arrow Therapeutics to obtain key preclinical data on safety and efficacy of their lead compound, IL-12-loaded nanopolymeric micelles. The funding will also enable manufacturing initiation in collaboration with external partners.
Red Arrow Therapeutics, Inc.
Founders: Takuya Miyazaki, Ph.D. , Horacio Cabral, Ph.D., and Rika Tajima, MPH
Founded Date: August 19, 2021
Address:
US Headquarters: 1 Broadway 14F, Cambridge, Massachusetts 02142
JP Office: Toranomon Hills Business Tower 1-17-1 Toranomon, Minato City, Tokyo 105-6490
Website: https://redarrowtx.com/
Contact: https://redarrowtx.com/contact/
Rika Tajima
[email protected]
SOURCE Red Arrow Therapeutics Inc.
